294 related articles for article (PubMed ID: 10720524)
41. Protective effect of acellular pertussis vaccines.
Blennow M; Hedenskog S; Granström M
Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):381-3. PubMed ID: 3137039
[TBL] [Abstract][Full Text] [Related]
42. Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population.
Fumimoto R; Otsuka N; Sunagawa T; Tanaka-Taya K; Kamiya H; Kamachi K
Vaccine; 2019 Apr; 37(18):2463-2469. PubMed ID: 30930008
[TBL] [Abstract][Full Text] [Related]
43. Comparison of anti-pertussis toxin ELISA and agglutination assays to assess immune responses to pertussis.
Khramtsov P; Bochkova M; Timganova V; Zamorina S; Rayev M
Infect Dis (Lond); 2017 Aug; 49(8):594-600. PubMed ID: 28335677
[TBL] [Abstract][Full Text] [Related]
44. Pertussis IgE and atopic disease.
Nilsson L; Grüber C; Granström M; Björkstén B; Kjellman NI
Allergy; 1998 Dec; 53(12):1195-201. PubMed ID: 9930597
[TBL] [Abstract][Full Text] [Related]
45. [Comparison of three ELISA techniques for the evaluation of IgG seroprevalence against Bordetella pertussis in children vaccinated with three doses of DTPwc].
Sanz JC; Fernández M; Sagües MJ; Ramírez R; Castañeda R; Barranco D; de Ory F
Enferm Infecc Microbiol Clin; 2002 Jan; 20(1):10-5. PubMed ID: 11820974
[TBL] [Abstract][Full Text] [Related]
46. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses.
Bergfors E; Trollfors B; Taranger J; Lagergård T; Sundh V; Zackrisson G
Int J Infect Dis; 1999; 3(3):140-6. PubMed ID: 10460925
[TBL] [Abstract][Full Text] [Related]
47. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
[TBL] [Abstract][Full Text] [Related]
48. Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6.
Blennow M; Granström M; Olin P; Tiru M; Jäätmaa E; Askelöf P; Sato Y
Dev Biol Stand; 1986; 65():185-90. PubMed ID: 3549397
[TBL] [Abstract][Full Text] [Related]
49. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants.
Knuf M; Schmitt HJ; Wolter J; Schuerman L; Jacquet JM; Kieninger D; Siegrist CA; Zepp F
J Pediatr; 2008 May; 152(5):655-60, 660.e1. PubMed ID: 18410769
[TBL] [Abstract][Full Text] [Related]
50. Serological correlates in whooping cough.
Granström M; Granström G
Vaccine; 1993; 11(4):445-8. PubMed ID: 8470429
[TBL] [Abstract][Full Text] [Related]
51. An improved ELISA system for the measurement of IgG antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) in human sera.
Sato Y; Sato H; Kodama H; Uchimura M; Miwa N; Kobayashi T; Yamamoto E; Fujita I; Kumamoto T
Dev Biol Stand; 1991; 73():167-74. PubMed ID: 1778310
[TBL] [Abstract][Full Text] [Related]
52. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model.
David S; van Furth R; Mooi FR
Vaccine; 2004 May; 22(15-16):1892-8. PubMed ID: 15121300
[TBL] [Abstract][Full Text] [Related]
53. Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin.
Nooitgedagt JE; de Greeff SC; Elvers BH; de Melker HE; Notermans DW; van Huisseling H; Versteegh FG
Clin Infect Dis; 2009 Oct; 49(7):1086-9. PubMed ID: 19725791
[TBL] [Abstract][Full Text] [Related]
54. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.
de Melker HE; Versteegh FG; Conyn-Van Spaendonck MA; Elvers LH; Berbers GA; van Der Zee A; Schellekens JF
J Clin Microbiol; 2000 Feb; 38(2):800-6. PubMed ID: 10655388
[TBL] [Abstract][Full Text] [Related]
55. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
[TBL] [Abstract][Full Text] [Related]
56. Determination of pertactin IgG antibodies for the diagnosis of pertussis.
Trollfors B; Lagergård T; Gunnarsson E; Taranger J
Clin Microbiol Infect; 2003 Jul; 9(7):585-9. PubMed ID: 12925096
[TBL] [Abstract][Full Text] [Related]
57. Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid.
Robbins JB; Schneerson R; Trollfors B; Taranger J; Lagergård T
Dev Biol Stand; 1998; 95():155-8. PubMed ID: 9855426
[TBL] [Abstract][Full Text] [Related]
58. The protective effect of immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome.
Essery SD; Raza MW; Zorgani A; MacKenzie DA; James VS; Weir DM; Busuttil A; Hallam N; Blackwell C
FEMS Immunol Med Microbiol; 1999 Aug; 25(1-2):183-92. PubMed ID: 10443507
[TBL] [Abstract][Full Text] [Related]
59. Serologic response and antibody-titer decay in adults with pertussis.
Heininger U; Cherry JD; Stehr K
Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
[TBL] [Abstract][Full Text] [Related]
60. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
Polewicz M; Gracia A; Garlapati S; van Kessel J; Strom S; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2013 Jun; 31(31):3148-55. PubMed ID: 23684829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
